A phase II trial of GDC-0084 for Glioblastoma.

Trial Profile

A phase II trial of GDC-0084 for Glioblastoma.

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs GDC 0084 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
    • 22 Aug 2017 According to a Novogen media release, the company expects to initiate this trial in the fourth quarter of 2017. Consultation with FDA expected to occur prior to initiation of the study to discuss key features of the clinical trial design.
    • 11 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top